Compare Mattel Inc (MAT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mattel Inc vs Novartis AG — how do they compare? Mattel Inc trades at $14.36 (market cap $4.11B), while Novartis AG trades at $156.62 (market cap $290.25B). The key difference: Novartis AG is far larger — about 70.6× Mattel Inc's market cap, and Novartis AG pays a 3.17% dividend while Mattel Inc pays none. Which is the better fit depends on your goals.
| MAT | NVS | |
|---|---|---|
Market Cap | $4.11B | $290.25B |
Sector | Consumer Cyclical | Health |
52-Week High | $22.16 | $168.62 |
52-Week Low | $13.05 | $113.50 |
Enterprise Value | $5.92B | $330.27B |
Dividend Yield | — | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mattel (MAT) trades at $14.165, down 0.94% today, with a bullish technical signal supported by moving averages. The stock shows attractive valuation with a P/E of 9.17 and P/S of 0.84, while recent earnings have been mixed with Q1 2026 beating expectations but Q3 and Q4 2025 missing. Revenue remains stable around $5.4B, and the company maintains strong brand collaborations, as seen with recent Hot Wheels and Barbie partnerships.
Outlook is cautiously optimistic given undervaluation and analyst consensus, but risks include stagnant sales, debt levels, and recent negative cash flow trends. The consensus price target is $14.60, suggesting limited upside from current levels, with investor sentiment divided between value opportunity and near-term headwinds.
Novartis (NVS) trades at $149.85, down 2.54% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results with $56.67B revenue and $13.98B net income, though recent quarterly EPS results have been mixed. Key developments include FDA approval for Fabhalta and the $1.5B acquisition of Myricx Bio to expand its oncology pipeline.
Outlook remains cautiously optimistic with 68% analyst hold ratings reflecting valuation concerns at 22.03 P/E. Near-term catalysts include Q2 2026 earnings and drug trial readouts, while risks involve pipeline execution and premium valuation pressure. The stock offers stability with robust profitability but faces growth execution tests ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
